You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Burkitt lymphoma (BL)

Showing 1 - 25 of 5,707
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Mature B-Cell Leukemia Burkitt Type, Burkitt Lymphoma (BL), Unclassifiable Lymphoma Between DCBL and BL Trial in Spain

Recruiting
  • Mature B-Cell Leukemia Burkitt Type
  • +2 more
  • Badalona, Barcelona, Spain
  • +28 more
Sep 17, 2021

Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

Suspended
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Burkitt Lymphoma, Lymphoblastic Lymphoma, Adult, Acute Lymphoblastic Leukemia, Adult Trial in Zhuhai (Thiotepa,

Recruiting
  • Burkitt Lymphoma
  • +2 more
  • Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen
  • Zhuhai, Guangdong, China
    The Fifth Affiliated Hospital of Sun Yat-sen University
Sep 25, 2023

Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Recruiting
  • Diffuse Large Cell Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Burkitt Lymphoma, Retinoblastoma, Diffuse Large B-cell Lymphoma Trial in Mwanza (mNavigator)

Active, not recruiting
  • Burkitt Lymphoma
  • +2 more
  • mNavigator
  • Mwanza, Lake Zone, Tanzania
    Bugando Medical Centre
Mar 7, 2022

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in United States (Zilovertamab vedotin)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +11 more
  • Zilovertamab vedotin
  • Duarte, California
  • +13 more
Jan 12, 2023

Diffuse Large B Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL) Trial in France (Real-life

Recruiting
  • Diffuse Large B Lymphoma (DLBCL)
  • +6 more
  • Real-life epidemiological platform of lymphoma in France
  • Arras, France
  • +36 more
Jun 25, 2021

Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease, DLBCL Trial in Kampala (Rituximab and Hyaluronidase Human,

Recruiting
  • Burkitt Lymphoma
  • +2 more
  • Rituximab and Hyaluronidase Human
  • +8 more
  • Kampala, Uganda
    UCI-Fred Hutch Cancer Centre
Mar 9, 2022

Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma Trial in United States (EPOCH-R,

Active, not recruiting
Has Results
  • Burkitt Lymphoma
  • +2 more
  • La Jolla, California
  • +29 more
Nov 2, 2021

HIV, Burkitt's Lymphoma Trial in Italy (Induction Phase, Consolidation Phase (on day +50), Intensification phase)

Completed
  • HIV
  • Burkitt's Lymphoma
  • Induction Phase
  • +4 more
  • Aviano (PN), Italy
  • +7 more
Aug 2, 2022

Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt

Not yet recruiting
  • Relapsed/Refractory Waldenstrom Macroglobulinemia
  • +3 more
  • Brexucabtagene Autoleucel
  • +2 more
  • (no location specified)
Sep 8, 2022

T-Acute Lymphoblastic Leukemia, Adult T Lymphoblastic Lymphoma Trial in United States (BL-8040, Nelarabine)

Terminated
  • T-Acute Lymphoblastic Leukemia
  • Adult T Lymphoblastic Lymphoma
  • Saint Louis, Missouri
  • +1 more
Jan 18, 2023

Burkitt's Lymphoma, Burkitt's Leukemia, Mediastinal Tumors Trial in Frankfurt (Adriamycin, Cyclophosphamide, Cytarabine)

Completed
  • Burkitt's Lymphoma
  • +4 more
  • Frankfurt, Germany
    University Hospital, Medical Dept. II
Aug 17, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2022

Lymphoma, Leukemia Trial in United States (CPI-613)

Recruiting
  • Lymphoma
  • Leukemia
  • Duarte, California
  • +9 more
Nov 28, 2022

Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)

Not yet recruiting
  • Non Hodgkin Lymphoma
  • +5 more
  • (no location specified)
Aug 4, 2023

DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)

Recruiting
  • Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 20, 2022

Leukemia, Acute Myeloid Leukemia in Remission, Myelodysplasia Trial (Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi))

Not yet recruiting
  • Leukemia
  • +12 more
  • Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
  • (no location specified)
Mar 20, 2023

Venetoclax Tablets Crushed and Dissolved Into a Solution

Not yet recruiting
  • Hematologic Malignancy
  • +18 more
  • 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
  • Cincinnati, Ohio
    Cincinnati Children's Hospital Medical Center
Nov 8, 2023

Adult Solid Tumor, Diffuse Large B Cell Lymphoma, Burkitt Lymphoma Trial in United Kingdom (AZD3965)

Completed
Has Results
  • Adult Solid Tumor
  • +2 more
  • Sutton, London, United Kingdom
  • +6 more
Feb 10, 2022

Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)

Recruiting
  • Grade 3a Follicular Lymphoma
  • +14 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Atlanta, Georgia
  • +1 more
May 31, 2022

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,

Active, not recruiting
  • B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
  • +11 more
  • Atlanta, Georgia
  • +1 more
Apr 18, 2022

Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the NCI (obinutuzumab, prednisone, Revlimid)

Recruiting
  • Lymphoma
  • +3 more
  • obinutuzumab
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 6, 2022

Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, MDS Trial in Tucson (Bendamustine, Cyclophosphamide)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +12 more
  • Tucson, Arizona
    The University of Arizona Cancer Center
Dec 13, 2022